Report Id: SNS/HC/2200 | July 2022 | Region: Global | 127 Pages
Biosimulation Market Size was valued at USD 3.26 billion in 2022, and is expected to reach USD 11.24 billion by 2030, and grow at a CAGR of 16.7% over the forecast period 2023-2030.
Biosimulation is a term used to use computer programs as a help to replicate systems and biological processes, especially for use in the pharmaceutical industry. It can be used in a variety of ways to improve drug availability and the creation of new drugs. To predict the effect of a particular drug on a biological component, biosimulation software usually contains data software and mathematical tools.
When a therapeutic molecule fails in the late stages of the drug discovery process, it wastes time and resources. Thus, it is essential to create a technology that would reveal the potential therapeutic molecule during the discovery phase. The global market for biosimulation is expanding mostly due to this factor. Additionally, the increase is encouraged by high healthcare costs, cutting-edge software, and improved simulation technologies. The biggest barriers to the worldwide biosimulation business include a lack of standard methodology, a limited understanding of biological processes, and a significant chance of medication failure in biosimulation. To lessen these limitations, the technique's accuracy might be improved, and it could be integrated with other approaches for more accurate forecasts.
Rise in R&D expenditures in the biotechnology and pharmaceutical sectors
Increasing regulatory bodies' use of biosimulation software
QSP Systems with the Latest Technology
Cost-saving measures for drug development and discovery
Market Development for Biosimilars and Biologics
Absence of Standards
Use of personalised medicine has increased
Utilization of Biosimulation Methods in the Development of Pediatric Drugs
Comparing the Complexity of Biological Systems and Procedures is difficult
Biosimulation and modeling specialists are in short supply
IMPACT OF COVID-19
The COVID-19 pandemic had a major effect on the healthcare sector, which included the biosimulation business. The requirement for quick testing and development of COVID-19 vaccine candidates sparked a demand for biosimulation tools and services. Known preclinical in vitro and in vivo datasets were used to undertake in silico modelling using a biosimulation tool called BIOiSIM, according to a study from April 2021 that was distributed in the National Center for Biotechnology Information. The goal of the study was to hasten the development of COVID-19-fighting drugs and therapies for pulmonary hypertension. The increase in studies that were similar to this one showed a favourable effect on the market expansion brought on by the increased demand for expedited COVID-19 medication development.
As example, a significant market participant named Certara worked with a number of pharmaceutical firms in August 2020. In order to make it simpler to develop vaccine candidates across various patient groups by employing virtual patients and trials, this collaboration was created to facilitate the development of a novel biosimulation technology. Prior to beginning any research in real life, it was also designed to offer insights. The Quantitative Systems Pharmacology (QSP) platform of the business included this new module. The business also launched the COVID-19 clinical outcomes database in July 2020 to provide up-to-date data on COVID-19 clinical trial results and observational research, globally.
By Product & Service
Software and services make up the two market segments for biosimulation. It is anticipated that the biosimulation software category will hold the biggest market share. The rapid expansion of this market is credited to the expansion of biosimulation software use by pharmaceutical and research firms as well as rising R&D spending on pharmaceutical research.
The market is divided into three categories: drug development, drug availability, and more. Drug development has accounted for a large part of the market because large pharmaceutical and biotechnology companies are increasingly applying to silico software to maximize the effectiveness of their existing pharmaceutical drugs by identifying and testing the best synergistic combination and dosage forms.
By Delivery Model
Subscription Models: By far the largest group in terms of delivery model, thanks to the benefits of subscription models including interoperability, cost-effectiveness, and flexibility.
Ownership Models: Due of the security advantages that come with ownership models, buyers choose to use them.
By End User
Research institutes, pharmaceutical and biotechnology businesses, contract research organizations (CROs), regulatory agencies, and other end users are different market segments of biosimulation (consulting firms, defense and development research organizations, nutrition companies, and food and agriculture companies). Companies in the fields of medicine and biotechnology are expected to respond with the largest share and have the highest predicted CAGR at the time of forecasting. The adoption of biosimulation solutions in the pharmaceutical and biotechnology industry is expected to further enhance the R&D budgets of pharmaceutical and biotechnology firms and the broad adoption of inorganic advancement systems by different biosimulation specialist organizations.
Some of the major key players are as follows: Advanced Chemistry Development, BioSimulation Consulting Inc., Certara, Dassault Systemes, Genedata AG, Chemical Computing Group ULC, Simulation Plus, Physiomics Plc, Rosa & Co. LLC, Schrodinger, Inc.
By Product & Service
By Delivery Model
By End User
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
North America, Europe, Asia, and LAMEA are the segments of the global biosimulation market. In terms of share value relative to total worldwide sales, North America dominates the biosimulation market and accounts for more than half of the market. The quest for new medicine molecules and the revocation of numerous drug patents in North America are major contributors to this growth. In terms of the global biosimulation market, where government initiatives are primarily driving growth, Europe is second only to North America. Asia-Pacific is a developing market where an increase of CROs is fueling growth.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2022||US$ 3.26 Billion|
|Market Size by 2030||US$ 11.24 Billion|
|CAGR||CAGR of 16.7% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Product & Service (Software, Services)
• By Application (Drug Development, Drug Discovery, Other Applications)
• By Delivery Model (Subscription Models, Ownership Models)
• By End User (Pharmaceutical and Biotechnology Companies, Research Institutes, Contract Research Organizations, Regulatory Authorities)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Advanced Chemistry Development, BioSimulation Consulting Inc., Certara, Dassault Systemes, Genedata AG, Chemical Computing Group ULC, Simulation Plus, Physiomics Plc, Rosa & Co. LLC, Schrodinger, Inc.|
|Key Drivers||• Rise in R&D expenditures in the biotechnology and pharmaceutical sectors
• Increasing regulatory bodies' use of biosimulation software
• QSP Systems with the Latest Technology
|Restraints||• Absence of Standards|
Frequently Asked Questions (FAQ) :
Manufacturer and service provider, research institutes, university and private libraries, suppliers and distributers.
The COVID-19 pandemic had a major effect on the healthcare sector, which included the biosimulation business. The requirement for quick testing and development of COVID-19 vaccine candidates sparked a demand for biosimulation tools and services.
The market is divided in four segments by Product & Service, By Application, By Delivery Model, and By End User
Ans. Emerging Technologies, and Use of personalised medicine has increased are the opportunities of the Biosimulation ma
Biosimulation Market Size was valued at USD 2.8 billion in 2021, and expected to reach USD 8.4 billion by 2028, and grow at a CAGR of 16.7% over the forecast period.
Table of Content
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
18.104.22.168 United Kingdom
22.214.171.124 South Korea
126.96.36.199 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Biosimulation Market Segmentation, By Product & Service
9. Biosimulation Market Segmentation, By Application
9.1 Drug Development
9.2 Drug Discovery
9.3 Other Applications
10. Biosimulation Market Segmentation, By Delivery Model
10.1 Subscription Models
10.2 Ownership Models
11. Biosimulation Market Segmentation, By End User
11.1 Pharmaceutical and Biotechnology Companies
11.2 Research Institutes
11.3 Contract Research Organizations
11.4 Regulatory Authorities
12. Regional Analysis
12.2 North America
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4.2 South Korea
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.3 South Africa
12.6 Latin America
12.6.3 Rest of Latin America
13.1 Advanced Chemistry Development
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.2 BioSimulation Consulting Inc.
13.4 Dassault Systemes
13.5 Genedata AG
13.6 Chemical Computing Group ULC
13.7 Simulation Plus
13.8 Physiomics Plc
13.9 Rosa & Co. LLC
13.10 Schrodinger, Inc.
14.1 Competitive Benchmark
14.2 Market Share analysis
14.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.